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Accepted 9 April 2010Granulosa cell tumors (GCTs) of the ovary that arise from
the sex cord stromal cells of the ovary accounts for 2e3% of
all ovarian cancers [1,2]. GCTs are characterized by a low
malignant potential, local spread, late recurrences (up to 20
years), and a high survival rate [3]. Two types of GCT have
been noted, the adult type and the juvenile type [4]. GCT may
be multicystic and contain serous fluid or blood. On histology,
adult GCT shows an exclusive population of granulosa cells,
an additional component of theca cells, fibroblasts, or both.
Call-Exner bodies (grooved nuclei arranged in rosettes) form
a microfollicular pattern resembling primodial follicles. GCT
can recur or metastasize many years after initial treatment.
Primary standard management of these tumors is surgery and
consists of hysterectomy and bilateral salpingo-oophorectomy.
For young patients with early Stage I disease who wish to
maintain fertility, conservative management is reasonable
and involves preservation of the uterus and the contralateral
ovary [5]. Laparoscopic management of an adnexal mass is
a common practice. A solid ovarian tumor requires clean and
complete removal of the adnexa. Rupture of an ovary
harboring the GCT may lead peritoneal implantation and lead
to the need for chemotherapy to treat any more advanced
disease.
We report herein a case with recurrent disseminated GCT
of the pelvis previously identified as a fibroma (this was
confirmed by reexamination to have contained a small amount
of GCT) of the ovary and was treated by laparoscopic resec-
tioning. The pathological diagnosis is discussed.
The patient is a 28-year-old female Gravida 0 Para 0 who
presented with an irregular menstrual cycle for 1 year and
infertility for 5 years. She had received laparoscopic right
oophorectomy because of fibroma 4 years ago at another
hospital. During the laparoscopic operation to treat the
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piece through subumbilical port site. Pathology at the time
confirmed that this was an ovarian fibroma.
After the initial surgery, her menstrual cycle became
regular but then the amount of menstruation began to decrease
again. Her menstrual cycle became irregular again 1 year ago.
She sought medical help because of amenorrhea for 3 months
and ultrasonogaphy revealed a hypoechoic mass of the left
ovary. No endometrial lesion was noted on ultrasound exam-
ination. Because of an impression of a benign ovarian lesion,
no tumor markers were examined preoperatively and she was
admitted for laparoscopic surgery.
During laparoscopy, multiple reddish soft nodules ranging
from 0.5 cm to 4 cm were found located in the parietal peri-
toneum area (Fig. 1A). The largest one, about 4 cm in diam-
eter, was located at the left lateral abdominal wall and at the
level of the umbilicus (Fig. 1B). The tumor was lipoma-like
and rich in blood supply (Fig. 1C and D). All the dissemi-
nated tumors in the abdominal cavity were retrieved by
endobag to prevent release of the tumor content into the pelvic
cavity. The uterus and left adnexa were normal in appearance.
The patient decided to receive conservative surgery based on
consideration of her future fertility.
Microscopic examination of the multiple lesions showed
that the tumors had cells with scanty cytoplasm with pale
round to oval nuclei. Nuclear grooves were identified in many
of the cells (Fig. 2A). The cells were arranged in micro-
follicular, trabecular, and diffuse patterns. Mitotic figures
were rare. The tumor cells were found to stain positive using
antibodies against smooth muscle actin, CD99, and inhibin
(Fig. 2BeD). In view of the typical histological morphology
and positive inhibin immunostaining, the lesion was diagnosed
as a recurrent GCT, adult type. As a result of the diagnosis of
GCT this time, we reviewed a previous surgical specimen
from the fibroma and found that the previous fibroma con-
tained a small amount of GCT. Thus, the final diagnosis is
recurrent GCT.
GCT of the ovary represents a rare form of ovarian
neoplasms and these can affect women at any age. In thecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Multiple reddish soft nodules ranging from 0.5 cm to 4 cm were located in the region of the parietal peritoneum. (B) The largest nodule, about 4 cm in
diameter, was located at the left lateral abdominal wall and at the level of the umbilicus. (C and D) The tumor was lipoma-like and rich in blood supply.
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larities or secondary amenorrhea, and cystic hyperplasia of the
endometrium is frequently present. GCTs are usually Stage I
at diagnosis but may recur 5e30 years after initial diagnosis.
Most GCTs have an indolent growth pattern, and recurrence is
not uncommon [6]. Patients with GCT require long-term
follow-up with regular history taking, physical examination,
and tumor marker studies because 17% of relapses can occur
more than 10 years after diagnosis [7]. The most common site
of recurrence is the pelvis.
Some patients have symptoms, such as abdominal pain and
menstrual irregularities, but diagnosis of GCT is often elusive
before surgery [8,9]. Complete surgical resectioning of the
abnormal ovary is the mainstay of the management of early
GCT. Young patients who desire future fertility may be
managed conservatively with the preservation of the uterus and
unaffected ovary [5]. Conservative surgery using laparoscopy
has been reported to be a safe and effective method for the
management of GCT [10]. For Stage IA disease, patients do not
require further treatment. Close follow-up involving serial
periodic measurements of the patient’s inhibin level is rec-
ommended. More advanced cases of the disease should receive
chemotherapy with the recommended regimen consisting of
bleomycin, etoposide, and cisplatinum [11].
Typical histological findings of a GCT include small, pale,
round to oval granulosa cells with characteristic “coffee-bean”
nuclei. Call-Exner bodies are present in 30e60% of GCTs.
Microfollicular, trabecular, insular, diffuse, or a mixture ofthese cell patterns are often found [12]. The differential
diagnosis of GCT includes endometrial stromal sarcoma,
undifferentiated carcinoma, and small cell carcinoma [9].
Immunostaining is also helpful with a definitive diagnosis.
Inhibin is an important tumor marker for confirmation of
a histological diagnosis of GCT [13].
Inhibin is a peptide hormone that participates in the regu-
lation of the pituitary-gonadal feedback system and is selec-
tively expressed by cells of sex cord-stromal derivation [14].
The ovary is the only source of inhibin secretion in nonpreg-
nant women. The serum level of inhibin is often elevated in
patients with granulose cell tumors [13]. It has been found to
be a more reliable marker for GCT than estradiol [13]. Using
immunohistological techniques, inhibin has been localized to
the granulose cell layer, the surrounding theca cells of
secondary follicles, and the hilar cells of the ovary [15]. The
presence of moderate to strong staining for inhibin in a histo-
logically indeterminate ovarian neoplasm provides strong
support for sex cord-stromal differentiation and practically
excludes a primary or metastatic carcinoma or a germ cell
neoplasm [14]. In the present case, strong positivity for
inhibin, smooth muscle actin, and CD99 confirmed the diag-
nosis of GCT.
The patient presented with multiple separate intrapelvic
masses, which is unusual for a primary tumor. GCT is known
to recur or metastasize years after initial diagnosis and treat-
ment and therefore there is strong correlation between meta-
static deposits in pelvic cavity and previous pathology.
Fig. 2. Microscopic features and immunohistochemistry of the granulosa cell tumors. (A) Microscopic features of the GCT (H&E stain, 100). (B) Microscopic
immunohistochemistry showing that the tumor is positive for smooth muscle actin as well as (C) anti-cd99 and (D) anti-inhibin (50). GCT¼ granulosa cell
tumor; H&E¼ hematoxylin and eosin.
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identifying the origin of a tumor, the extent of disease, and its
respectability [9]. Therapeutic procedures for benign lesions,
such as ovarian cysts or cystic teratomas, have been previously
described. However, laparoscopic resection of ovarian malig-
nancies has not yet been generally advocated. Nonetheless,
this type of minimally invasive resectioning only means that
there is a different type of access to the tumor and does not
compromise surgical safety [10,16]. The use of an endoscopic
retrieval bag into which the mass can be placed and reduced in
size without spillage into the peritoneal cavity facilitates the
safe removal of the mass. Frozen sectioning also can help with
the diagnosis during the operation.
In conclusion, laparoscopic management of an unknown
adnexal mass is acceptable and even preferable to laparotomy.
Clean removal of the adnexal tumor without spillage of tumor
contents needs to be emphasized. If the tumor is ruptured, then
the patient should undergo an additional surgical procedure
and receive adjuvant chemotherapy to treat any locally
advanced disease. Immunostaining can help to differentiate
GCTs from other neoplasms.
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